stockrow
Monday 9 November 2026
Export KROS’s income statement to Excel — free account
Keros Therapeutics, Inc.
KROSKeros Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $244.1 million, up 6,775.0% from fiscal 2024.
- Revenue
- +120.2%
- EPS
- +494.4%
- Free cash flow
- +6.87%
Quarter to September 2026, against a year earlier
9.36
0.09
−0.95%
Follow KROS
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
10.95 | 0.00 | — | 0.00 |
P/S ratio |
3.11 | 6.53 | — | 4.12 | |
P/FCF ratio |
7.15 | 0.00 | — | 0.00 | |
P/Operating CF |
(27.77) | (61.41) | — | 66.87 | |
P/B ratio |
2.50 | 0.76 | — | 0.81 | |
Price to Tangible BV |
2.50 | 0.76 | — | 0.81 | |
EV/Sales |
1.93 | (1.95) | — | (0.60) | |
EV/EBITDA |
6.81 | 0.60 | — | 0.46 | |
EV/Operating CF |
4.38 | 1.13 | — | 0.68 | |
EV/FCF |
4.44 | 1.11 | — | 0.68 | |
Quick Ratio |
14.36 | 22.11 | 21.38 | 16.36 | |
Current Ratio |
15.45 | 22.62 | 21.96 | 18.14 | |
Net Debt/EBITDA |
9.96 | 11.05 | 8.44 | (19.65) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.51 | 0.06 | 0.00 | 0.10 | |
Operating CF/Net income |
1.16 | 0.15 | 0.71 | 0.24 | |
Capex/Depreciation |
(0.33) | (0.18) | (0.39) | (0.15) | |
Research and Development Expense of Revenue |
4,652.47% | 4,386.10% | 0.00% | 51.22% | |
Selling, General and Administrative Expense of Revenue |
3,050.13% | 2,764.85% | 0.00% | 16.75% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
1,897.40% | 1,689.10% | 0.00% | 10.51% | |
Graham Net Nets |
0.37 | 1.22 | — | 1.14 | |
Graham Number |
18.46 | 0.00 | — | 0.00 | |
Earnings Yield |
9.14% | (27.26%) | — | (24.65%) | |
Free Cash Flow Yield |
13.98% | (26.88%) | — | (21.29%) | |
Revenue per Share |
0.01 | 0.02 | 0.00 | 2.01 | |
Operating CF per Share |
(0.73) | (0.18) | (1.03) | 0.17 | |
Capex per Share |
0.00 | 0.00 | (0.01) | 0.00 | |
Free Cash Flow per Share |
(0.74) | (0.18) | (1.04) | 0.17 | |
Cash per Share |
7.72 | 14.34 | 13.01 | 13.05 | |
Shareholders Equity per Share |
8.14 | 14.55 | 13.25 | 14.03 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
8.14 | 14.55 | 13.25 | 14.03 | |
Free Cash Flow |
(27.43) | (3.60) | (20.58) | 3.33 | |
Working Capital |
295.02 | 277.82 | 254.73 | 271.78 | |
Capital Expenditures |
(0.13) | (0.07) | (0.15) | (0.06) | |
Net Current Asset Value |
280.55 | 264.01 | 241.60 | 259.36 | |
EV/EBIT |
6.96 | 0.59 | — | 0.45 | |
Capex to Sales |
0.35 | 0.20 | 0.00 | 0.00 | |
Price to Operating Income |
11.22 | 0.00 | — | 0.00 | |
| Other line items | |||||
Average Receivables |
4.28 | 9.97 | 9.03 | — | |
Average Payables |
3.28 | 4.06 | 3.54 | 3.04 | |
Average Assets |
476.95 | 548.43 | 522.38 | 525.08 | |
Average Common Equity |
437.34 | 507.25 | 484.53 | 491.34 |
Columns are period end dates · fundamentals updated 5 Nov 2026